Antimicrobial dosing concepts and recommendations for critically Ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis

Pharmacotherapy

Volumn 29, Issue 5, 2009, Pages 562-577

  Heintz, Brett H ^a,b   Matzke, Gary R ^c   Dager, William E ^a,b,d,e  

^a TOURO UNIVERSITY CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antimicrobials; Critically ill; Dialysis; Pharmacodynamics; Pharmacokinetics; Renal failure; Renal replacement therapy

Indexed keywords

ACICLOVIR; AMIKACIN; AMINOGLYCOSIDE; AMPHOTERICIN B DEOXYCHOLATE; AMPICILLIN; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; AZITHROMYCIN; CEFAZOLIN; DAPTOMYCIN; DIHYDROCODEINE; FLUCONAZOLE; GANCICLOVIR; GENTAMICIN; IMIPENEM; ITRACONAZOLE; KETOLIDE; LINEZOLID; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; NAFCILLIN; PENICILLIN G; PROPRANOLOL; SULTAMICILLIN; TIGECYCLINE; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ACUTE KIDNEY FAILURE; ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; BACTEREMIA; CHRONIC KIDNEY DISEASE; CRITICALLY ILL PATIENT; DATA BASE; DIALYSIS; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG ELIMINATION; EVIDENCE BASED MEDICINE; HUMAN; MEDLINE; PHARMACODYNAMICS; PRACTICE GUIDELINE; RENAL REPLACEMENT THERAPY; REVIEW; SCIENTIFIC LITERATURE; SEPSIS; SEPTIC SHOCK; TREATMENT INDICATION;

ANTI-INFECTIVE AGENTS; CLINICAL PROTOCOLS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; CRITICAL ILLNESS; HUMANS; KIDNEY FAILURE, ACUTE; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; RENAL REPLACEMENT THERAPY;

EID: 66249094202     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.5.562     Document Type: Review

References (82)

1. Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003;115:529-35.
2. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003;31:2742-51.
3. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000;118:146-55.
4. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999;115:462-74.
5. Luna CM, Vujacich P, Niederman MS, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997;111:676-85.
6. Rello J, Gallego M, Mariscal D, Sonora R, Valles J. The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med 1997;156:196-200.
7. Valles J, Rello J, Ochagavia A, Garnacho J, Alcala MA. Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival. Chest 2003;123:1615-24.
8. Matzke GR, Dowling T. Dosing concepts in renal dysfunction. In: Murphy JE, ed. Clinical pharmacokinetics. Bethesda, MD: American Society of Health-System Pharmacists, 2008:427-43.
9. Demirkilic U, Kuralay E, Yenicesu M, et al. Timing of replacement therapy for acute renal failure after cardiac surgery. J Card Surg 2004;19:17-20.
10. Palevsky PM, Baldwin I, Davenport A, Goldstein S, Paganini E. Renal replacement therapy and the kidney: minimizing the impact of renal replacement therapy on recovery of acute renal failure. Curr Opin Crit Care 2005;11:548-54.
11. Swartz RD, Messana JM, Orzol S, Port FK. Comparing continuous hemofiltration with hemodialysis in patients with severe acute renal failure. Am J Kidney Dis 1999;34:424-32.
12. Clermont G, Acker CG, Angus DC, Sirio CA, Pinsky MR, Johnson JP. Renal failure in the ICU: comparison of the impact of acute renal failure and end-stage renal disease on ICU outcomes. Kidney Int 2002;62:986-96.
13. Angus DC, Linde-Zwirbe WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated cost of care. Crit Care Med 2001;29:1303-10.
14. Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005;294:813-18.
15. Metnitz PG, Krenn CG, Steltzer H, et al. Effect of acute renal failure requiring renal replacement therapy on outcome in critically ill patients. Crit Care Med 2002;30:2051-8.
16. Xue JL, Daniels F, Star RA, et al. Incidence and mortality of acute renal failure in Medicare beneficiaries, 1992 to 2001. J Am Soc Nephrol 2006;17:1135-42.
17. Brivet FG, Kleinknecht DJ, Loirat P, Landais PJ, for the French Study Group on Acute Renal Failure. Acute renal failure in intensive care units: causes, outcome, and prognostic factors of hospital mortality; a prospective, multicenter study. Crit Care Med 1996;24:192-8.
18. de Mendonca A, Vincent JL, Suter PM, et al. Acute renal failure in the ICU: risk factors and outcome evaluated by the SOFA score. Intensive Care Med 2000;26:915-21.
19. Liano F, Junco E, Pascual J, Madero R, Verde E, for the Madrid Acute Renal Failure Study Group. The spectrum of acute renal failure in the intensive care unit compared with that seen in other settings. Kidney Int Suppl 1998;66:S16-24.
20. Taber SS, Mueller BA. Drug-associated renal dysfunction. Crit Care Clin 2006;22:357-74.
21. Bates DW, Cullen DJ, Laird N, et al, for the ADE Prevention Study Group. Incidence of adverse drug events and potential adverse drug events: implications for prevention. JAMA 1995;274:29-34.
22. Leape LL, Cullen DJ, Clapp MD, et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA 1999;282:267-70.
23. Cantu TG, Ellerbeck EF, Yun SW, Castine SD, Kornhauser DM. Drug prescribing for patients with changing renal function. Am J Hosp Pharm 1992;49:2944-8.
24. Bohler J, Donauer J, Keller F. Pharmacokinetic principles during continuous renal replacement therapy: drugs and dosage. Kidney Int Suppl 1999;Nov(72):S24-8.
25. Arzuaga A, Maynar J, Gascon AR, et al. Influence of renal function on the pharmacokinetics of piperacillin/tazobactam in intensive care unit patients during continuous venovenous hemofiltration. J Clin Pharmacol 2005;45:168-76.
26. Keller E, Bohler J, Busse-Grawitz A, Reetze-Bonorden P, Krumme B, Schollmeyer P. Single-dose kinetics of piperacillin during continuous arteriovenous hemodialysis in intensive care patients. Clin Nephrol 1995;43(suppl 1):S20-3.
27. Tegeder I, Bremer F, Oelkers R, et al. Pharmacokinetics of imipenem-cilastatin in critically ill patients undergoing continuous venovenous hemofiltration. Antimicrob Agents Chemother 1997;41:2640-5.
28. Tegeder I, Neumann F, Bremer F, Brune K, Lotsch J, Geisslinger G. Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration. Clin Pharmacol Ther 1999;65:50-7.
29. Thalhammer F, Horl WH. Pharmacokinetics of meropenem in patients with renal failure and patients receiving renal replacement therapy. Clin Pharmacokinet 2000;39:271-9.
30. Matzke GR, Comstock TJ. Influence of renal function and dialysis on drug disposition. In: Burton ME, Shaw LM, Schentag JJ, Evans WE, eds. Applied pharmacokinetics and pharmacodynamics. Philadelphia: Lippincott Williams & Wilkins, 2006:187-212.
31. Dressman JB, Bass P, Ritschel WA, Friend DR, Rubinstein A, Ziv E. Gastrointestinal parameters that influence oral medications. J Pharm Sci 1993;82:857-72.
32. Nolin TD. Altered nonrenal drug clearance in ESRD. Curr Opin Nephrol Hypertens 2008;17:555-9.
33. Nolin TD, Naud J, Leblond FA, et al. Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Ther 2008;83:809-11.
34. Michaud J, Nolin TD, Naud J, et al. Effect of hemodialysis on hepatic cytochrome P450 functional expression. J Pharmacol Sci 2008;108:157-63.
35. Guevin C, Michaud J, Naud J, Leblond FA, Pichette V. Downregulation of hepatic cytochrome p450 in chronic renal failure: role of uremic mediators. Br J Pharmacol 2002;137:1039-46.
36. Matzke GR, Frye RF. Drug therapy individualization for patients with renal insufficiency. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach. New York: McGraw-Hill Medical, 2008:833-44.
37. Mueller BA, Scarim SK, Macias WL. Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofiltration. Am J Kidney Dis 1993;21:172-9.
38. Boucher BA, Wood GC, Swanson JM. Pharmacokinetic changes in critical illness. Crit Care Clin 2006;22:255-71.
39. De Paepe P, Belpaire FM, Buylaert WA. Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock. Clin Pharmacokinet 2002;41:1135-51.
40. DeBellis RJ, Smith BS, Cawley PA, Burniske GM. Drug dosing in critically ill patients with renal failure: a pharmacokinetic approach. J Intensive Care Med 2000;15:273-313.
41. Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 2005;44:1009-34.
42. Pea F, Viale P, Pavan F, Furlanut M. Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy. Clin Pharmacokinet 2007;46:997-1038.
43. Pinder M, Bellomo R, Lipman J. Pharmacological principles of antibiotic prescription in the critically ill. Anaesth Intensive Care 2002;30:134-44.
44. Roberts JA, Lipman J. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet 2006;45:755-73.
45. Schetz M. Drug dosing in continuous renal replacement therapy: general rules. Curr Opin Crit Care 2007;13:645-51.
46. DelDot ME, Lipman J, Tett SE. Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration. Br J Clin Pharmacol 2004;58:259-68.
47. Dager WE, King JH. Aminoglycosides in intermittent hemodialysis: pharmacokinetics with individual dosing. Ann Pharmacother 2006;40:9-14.
48. Amsden GW, Ballow CH, Bertino JS, Kashuba AD. Pharmacokinetics and pharmacodynamics of anti-infective agents. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. Philadelphia: Elsevier, Inc, 2005:271-81.
49. Rybak MJ. Pharmacodynamics: relation to antimicrobial resistance. Am J Med 2006;119:S37-44.
50. Lodise TP, Lomaestro BM, Drusano GL. Application of antimicrobial pharmacodynamic concepts into clinical practice:focus on β-lactam antibiotics. Insights of the society of infectious disease pharmacists. Pharmacotherapy 2006;26:1320-32.
51. Thomson Micromedex. Micromedex healthcare series: DRUGDEX system 2008. Greenwood Village, CO: Thomson Micromedex, 2008.
52. Kubin C, Dzierba A. The effects of continuous renal replacement on anti-infective therapy in the critically ill. J Pharm Practice 2005;18:109-17.
53. Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis 2005;41:1159-66.
54. Aberg JA, Gray LD, Long JK. Infectious dseases handbook, 6th ed. Hudson, OH: Lexi-Comp, 2006.
55. Joy MS, Matzke GR, Armstrong DK, Marx MA, Zarowitz BJ. A primer on continuous renal replacement therapy for critically ill patients. Ann Pharmacother 1998;32:362-75.
56. Huang Z, Letteri JJ, Clark WR, et al. Operational characteristics of continuous renal replacement modalities used for critically ill patients with acute kidney injury. Int J Artif Organs 2008;31:525-34.
57. Bouchard J, Weideman C, Mehta RL. Renal replacement therapy in acute kidney injury: intermittent versus continuous? How much is enough? J Nat Kidney Foundation 2008;15:235-47.
58. Foote EF, Manley HJ. Hemodialysis and peritoneal dialysis. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach. New York: McGraw-Hill Medical, 2008:O103-17.
59. Scheetz MH, Scarsi KK, Ghossein C, Hurt KM, Zembower TR, Postelnick MJ. Adjustment of antimicrobial dosages for continuous venovenous hemofiltration based on patientspecific information. Clin Infect Dis 2006;42:436-8.
60. Isla A, Gascon AR, Maynar J, Arzuaga A, Toral D, Pedraz JL. Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients. Clin Ther 2005;27:599-608.
61. Malone RS, Fish DN, Abraham E, Teitelbaum I. Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother 2001;45:3148-55.
62. Mariat C, Venet C, Jehl F, et al. Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic evaluation and dose recommendation [online exclusive article]. Crit Care 2006;10:R26. Available from http://ccforum.com/content/10/1/R26.
63. Li J, Rayner CR, Nation RL, et al. Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother 2005;49:4814-15.
64. Churchwell MD, Pasko DA, Mueller BA. Daptomycin clearance during modeled continuous renal replacement therapy. Blood Purif 2006;24:548-54.
65. Burkhardt O, Joukhadar C, Traunmuller F, Hadem J, Welte T, Kielstein JT. Elimination of daptomycin in a patient with acute renal failure undergoing extended daily dialysis. J Antimicrob Chemother 2008;61:224-5.
66. Bergner R, Hoffmann M, Riedel KD, et al. Fluconazole dosing in continuous veno-venous haemofiltration (CVVHF): need for a high daily dose of 800 mg. Nephrol Dial Transplant 2006;21:1019-23.
67. Yagasaki K, Gando S, Matsuda N, et al. Pharmacokinetics and the most suitable dosing regimen of fluconazole in critically ill patients receiving continuous hemodiafiltration. Intensive Care Med 2003;29:1844-8.
68. Sowinski KM, Magner SJ, Lucksiri A, Scott MK, Hamburger RJ, Mueller BA. Influence of hemodialysis on gentamicin pharmacokinetics, removal during hemodialysis, and recommended dosing. Clin J Am Soc Nephrol 2008;3:355-61.
69. Fish DN, Teitelbaum I, Abraham E. Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother 2005;49:2421-8.
70. Kielstein JT, Czock D, Schopke T, et al. Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis. Crit Care Med 2006;34:51-6.
71. Giles LJ, Jennings AC, Thomson AH, Creed G, Beale RJ, McLuckie A. Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration. Crit Care Med 2000;28:632-7.
72. Krueger WA, Neeser G, Schuster H, et al. Correlation of meropenem plasma levels with pharmacodynamic requirements in critically ill patients receiving continuous veno-venous hemofiltration. Chemotherapy 2003;49:280-6.
73. Robatel C, Decosterd LA, Biollaz J, Eckert P, Schaller MD, Buclin T. Pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patients. J Clin Pharmacol 2003;43:1329-40.
74. Ariano RE, Fine A, Sitar DS, Rexrode S, Zelenitsky SA. Adequacy of a vancomycin dosing regimen in patients receiving high-flux hemodialysis. Am J Kidney Dis 2005;46:681-7.
75. Klansuwan N, Ratanajamit C, Kasiwong S, Wangsiripaisan A. Clearance of vancomycin during high-efficiency hemodialysis. JMed Assoc Thai 2006;89:986-91.
76. Launay-Vacher V, Izzedine H, Mercadal L, Deray G. Clinical review: use of vancomycin in haemodialysis patients. Crit Care 2002;6:313-16.
77. Pai AB, Pai MP. Vancomycin dosing in high flux hemodialysis: a limited-sampling algorithm. Am J Health Syst Pharm 2004;61:1812-16.
78. Pallotta KE, Manley HJ. Vancomycin use in patients requiring hemodialysis: a literature review. Semin Dial 2008;21:63-70.
79. Matzke GR, Clermont G. Clinical pharmacology and therapeutics. In: Murray P, Brady HR, Hall JB, eds. Intensive care in nephrology. London, England: Martin Dunitz, 2005:245-66.
80. Bugge JF. Pharmacokinetics and drug dosing adjustments during continuous venovenous hemofiltration or hemodiafiltration in critically ill patients. Acta Anaesthesiol Scand 2001;45:929-34.
81. Dager WE. Filtering out important considerations for developing drug-dosing regimens in extended daily dialysis. Crit Care Med 2006;34:240-1.
82. Lewington A. Renal replacement therapy in the critically ill patient with acute kidney injury. Hemodial Int 2007;11:S39-43.